Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
Holding VERA?
Track your performance easily
VERA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.24 - $50.78
Previous Close$36.62
Volume1.12M
Average Volume (3M)769.79K
Market Cap
$2.00B
Enterprise Value$1.65B
Total Cash (Recent Filing)$403.66M
Total Debt (Recent Filing)$53.26M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 08, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding54,701,217
10 Day Avg. Volume672,659
30 Day Avg. Volume769,795
Standard Deviation0.37
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)5.56
Price to Sales (P/S)1018.27
Price to Cash Flow (P/CF)-14.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue857.24
Enterprise Value/Gross Profit857.24
Enterprise Value/Ebitda-23.81
Forecast
1Y Price Target
$63.00Price Target Upside71.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Vera Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive 72-week data from the Phase IIb ORIGIN study in IgA nephropathy (IgAN) show sustained reductions in Gd-IgA1 and proteinuria, along with eGFR stabilization.
Market OpportunityVertex's acquisition of Alpine for approximately $4.9 billion in cash underscores the significant commercial potential of BLyS/APRIL inhibitors.
Safety ProfileBoth doses of the treatment have been generally well-tolerated with no severe infections or significant adverse effects reported, pointing to a favorable safety profile.
Bears Say
Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Financial PerformanceVERA reported a net loss of $96MM for the year-end, indicating financial challenges.
Investment Banking ServicesJ.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Vera Therapeutics.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERA FAQ
What was Vera Therapeutics’s price range in the past 12 months?
Vera Therapeutics lowest stock price was $9.24 and its highest was $50.78 in the past 12 months.
What is Vera Therapeutics’s market cap?
Currently, no data Available
When is Vera Therapeutics’s upcoming earnings report date?
Vera Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is 107 days ago.
How were Vera Therapeutics’s earnings last quarter?
Vera Therapeutics released its earnings results on May 09, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.53 by -$0.03.
Is Vera Therapeutics overvalued?
According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued.
Does Vera Therapeutics pay dividends?
Vera Therapeutics does not currently pay dividends.
What is Vera Therapeutics’s EPS estimate?
Vera Therapeutics’s EPS estimate is -$0.56.
How many shares outstanding does Vera Therapeutics have?
Vera Therapeutics has 54,701,218 shares outstanding.
What happened to Vera Therapeutics’s price movement after its last earnings report?
Vera Therapeutics reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.53. Following the earnings report the stock price went down -5.808%.
Which hedge fund is a major shareholder of Vera Therapeutics?
Among the largest hedge funds holding Vera Therapeutics’s share is Woodline Partners LP. It holds Vera Therapeutics’s shares valued at 41M.
---
Vera Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.00 (71.43% Upside)
$63.00 (71.43% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.07%
12-Months-Change
Fundamentals
Return on Equity
-36.89%
Trailing 12-Months
Asset Growth
100.07%
Trailing 12-Months
Company Description
Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
---
VERA Stock 12 Month Forecast
Average Price Target
$63.00
▲(71.43% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Kala Pharmaceuticals
―
Sangamo Biosciences
―
Kodiak Sciences
―
Best Analysts Covering VERA
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+164.05%
reiterated a buy rating 10 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +164.05% per trade.
---